ADC Therapeutics posts preliminary 2025 revenue of about $73M
Source: SeekingAlpha
2026-01-08 16:25:12 ET
More on ADC Therapeutics
- ADC Therapeutics SA (ADCT) Discusses Updated Results From LOTIS-7 Trial Evaluating ZYNLONTA Plus Glofitamab in Relapsed or Refractory DLBCL - Slideshow
- ADC Therapeutics SA (ADCT) Discusses Updated Results From LOTIS-7 Trial Evaluating ZYNLONTA Plus Glofitamab in Relapsed or Refractory DLBCL Transcript
- ADC Therapeutics SA (ADCT) Q3 2025 Earnings Call Transcript
- ADC Therapeutics signals ZYNLONTA peak revenue potential of $600M–$1B in U.S. with expanded clinical milestones
- ADC Therapeutics Q3 Earnings Preview
Read the full article on Seeking Alpha
For further details see:
ADC Therapeutics posts preliminary 2025 revenue of about $73M
ADC Therapeutics SA
NASDAQ: ADCT
ADCT Trading
0.12% G/L:
$4.09 Last:
202,024 Volume:
$4.07 Open:
ADCT Latest News
March 03, 2026 07:15:00 am
ADC Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on March 10, 2026
February 23, 2026 07:15:00 am
ADC Therapeutics Announces Amended HealthCare Royalty Financing Agreement
ADCT Stock Data
$486,217,661
104,923,913
12.45%
40
N/A
Biotechnology & Life Sciences
Healthcare
CH
Epalinges
